Molecular docking analysis of guaiacin and chalcone from nutmeg (Myristica fragrans) as novel HSP90A inhibitors for skin cancer treatment
Abstract
Skin cancer represents one of the most prevalent malignancies globally, with Indonesia reporting the third highest incidence among cancer types. Despite advances in treatment, there remains a critical need for novel therapeutic agents. Heat Shock Protein 90 Alpha (HSP90A) has emerged as a promising target for cancer therapy due to its critical role in stabilizing oncogenic proteins. This study aimed to evaluate the potential of guaiacin and chalcone from nutmeg (Myristica fragrans) as HSP90A inhibitors for skin cancer treatment through computational analysis. Molecular docking was performed using AutoDock Tools with the HSP90A crystal structure (PDB ID: 2VCJ). The compounds were assessed for binding affinity, molecular interactions, and drug-likeness properties according to Lipinski's Rule of Five. Redocking validation yielded an RMSD of 1.24 Å, confirming protocol reliability. Guaiacin demonstrated promising binding affinity (-7.40 kcal/mol) with key hydrogen bonds to Asp93 and Lys58, while chalcone showed moderate affinity (-5.99 kcal/mol) with a single hydrogen bond to Thr184. Both compounds exhibited favorable drug-like properties with high predicted gastrointestinal absorption. Guaiacin emerges as a promising natural HSP90A inhibitor candidate with binding energy exceeding the stability threshold (-7.00 kcal/mol) and interactions with critical residues in the ATP-binding pocket, providing a foundation for further development of nutmeg-derived compounds as potential anticancer agents.
References
Hardianto A, Qodir N, Roflin E, Indra B. Incidence and Characteristics of Skin Cancer Patients at Dr. Mohammad Hoesin General Hospital, Palembang. Indonesian Journal of Cancer. 2025;19: 90-95. https://doi.org/10.33371/ijoc.v19i1.1280
Atanasov AG, Waltenberger B, Pferschy-Wenzig E-M, Linder T, Wawrosch C, Uhrin P, et al. Discovery and resupply of pharmacologically active plant-derived natural products: A review. Biotechnology Advances. 2015;33: 1582-1614. https://doi.org/10.1016/j.biotechadv.2015.08.001
Ginting B, Mustanir M M, Nurdin N N, Maulidna M M, Murniana M M, Safrina S S. Evaluation of Antioxidant and Anticancer Activity of Myristica fragrans Houtt. Bark. PJ. 2021;13: 780-786. https://doi.org/10.5530/pj.2021.13.99
Xie X, Zhang N, Li X, Huang H, Peng C, Huang W, et al. Small-molecule dual inhibitors targeting heat shock protein 90 for cancer targeted therapy. Bioorganic Chemistry. 2023;139: 106721. https://doi.org/10.1016/j.bioorg.2023.106721
Saxena AK, Saxena S, Chaudhaery SS. Molecular modelling and docking studies on heat shock protein 90 (Hsp90) inhibitors. SAR and QSAR in Environmental Research. 2010;21: 1-20. https://doi.org/10.1080/10629360903560504
Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer. 2010;10: 537-549. https://doi.org/10.1038/nrc2887
Ferreira L, Dos Santos R, Oliva G, Andricopulo A. Molecular Docking and Structure-Based Drug Design Strategies. Molecules. 2015;20: 13384-13421. https://doi.org/10.3390/molecules200713384
Chen X, Li H, Tian L, Li Q, Luo J, Zhang Y. Analysis of the Physicochemical Properties of Acaricides Based on Lipinski's Rule of Five. Journal of Computational Biology. 2020;27: 1397-1406. https://doi.org/10.1089/cmb.2019.0323
Neckers L, Workman P. Hsp90 Molecular Chaperone Inhibitors: Are We There Yet? Clinical Cancer Research. 2012;18: 64-76. https://doi.org/10.1158/1078-0432.CCR-11-1000
Huang N, Shoichet BK, Irwin JJ. Benchmarking Sets for Molecular Docking. J Med Chem. 2006;49: 6789-6801. https://doi.org/10.1021/jm0608356
Lauria A, Ippolito M, Almerico AM. Inside the Hsp90 inhibitors binding mode through induced fit docking. Journal of Molecular Graphics and Modelling. 2009;27: 712-722. https://doi.org/10.1016/j.jmgm.2008.11.004
García-Ortegón M, Simm GNC, Tripp AJ, Hernández-Lobato JM, Bender A, Bacallado S. DOCKSTRING: Easy Molecular Docking Yields Better Benchmarks for Ligand Design. J Chem Inf Model. 2022;62: 3486-3502. https://doi.org/10.1021/acs.jcim.1c01334
Hyun SY, Le HT, Nguyen C-T, Yong Y-S, Boo H-J, Lee HJ, et al. Development of a novel Hsp90 inhibitor NCT-50 as a potential anticancer agent for the treatment of non-small cell lung cancer. Sci Rep. 2018;8: 13924. https://doi.org/10.1038/s41598-018-32196-6
Kyle Hadden M, Hill SA, Davenport J, Matts RL, Blagg BSJ. Synthesis and evaluation of Hsp90 inhibitors that contain the 1,4-naphthoquinone scaffold. Bioorganic & Medicinal Chemistry. 2009;17: 634-640. https://doi.org/10.1016/j.bmc.2008.11.064
Sakkiah S, Thangapandian S, John S, Kwon YJ, Lee KW. 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors. European Journal of Medicinal Chemistry. 2010;45: 2132-2140. https://doi.org/10.1016/j.ejmech.2010.01.016
Rampogu S, Parate S, Parameswaran S, Park C, Baek A, Son M, et al. Natural compounds as potential Hsp90 inhibitors for breast cancer-Pharmacophore guided molecular modelling studies. Computational Biology and Chemistry. 2019;83: 107113. https://doi.org/10.1016/j.compbiolchem.2019.107113
AbdElmoniem N, H. Abdallah M, M. Mukhtar R, Moutasim F, Rafie Ahmed A, Edris A, et al. Identification of Novel Natural Dual HDAC and Hsp90 Inhibitors for Metastatic TNBC Using e-Pharmacophore Modeling, Molecular Docking, and Molecular Dynamics Studies. Molecules. 2023;28: 1771. https://doi.org/10.3390/molecules28041771
Zarguan I, Ghoul S, Belayachi L, Benjouad A. Plant-Based HSP90 Inhibitors in Breast Cancer Models: A Systematic Review. IJMS. 2024;25: 5468. https://doi.org/10.3390/ijms25105468
Copyright (c) 2023 Authors
This work is licensed under a Creative Commons Attribution 4.0 International License.
